

Eugenia uniflora L. Leaf Extract Ameliorated Metabolic Traits and Reduced Visceral Adiposity in Rat Model of Metabolic Syndrome

Evyy Sulistyoningrum¹ , Dede Syifa Izzatul Aulia¹ 

ABSTRACT

Background

The prevalence of metabolic syndrome has risen globally in recent years. Visceral fat and insulin resistance have been reported as crucial factors for chronic inflammation that caused several complications of metabolic syndrome. Pitanga (Myrtaceae) are extensively dispersed and have long been utilized as herbal treatments and reported to have antioxidant and antidiabetic activities.

Objective

Investigate the activities of *Eugenia uniflora* L. leaf extract on the metabolic syndrome components; epididymal fat and pancreas histology in a rat model.

Method

The experiment followed a post-test only design using 25 male Wistar rats. The animals were randomly allocated into five equal groups: normal, metabolic syndrome (MS), MS + telmisartan 8 mg/kg as standard treatment; MS + *Eugenia uniflora* L. leaf extract (ELE) 50 mg/kg; and MS + ELE 100 mg/kg. Metabolic syndrome was induced by high-fat diets and 20% fructose in drinking water for 8 weeks simultaneously with standard treatment and extracts. At day 57, metabolic syndrome components were measured, and epididymal fat as well as the pancreas were taken for histological analysis.

Results

Administration of ELE 100 mg/kg improved metabolic syndrome components, including reduced blood glucose and triglycerides levels; reduced systolic blood pressure and Lee Index, also increased HDL-cholesterol levels. The ELE 100 mg/kg also reduced epididymal adipocyte area, and the result was comparable with telmisartan. However, neither telmisartan nor ELE affected the size of pancreatic islets.

Conclusion

ELE improves metabolic syndrome components and reduces visceral adiposity in rat models induced by HFD and fructose combination.

Keyword

metabolic syndrome; *Eugenia*, high-fat diet; pancreas; adipocyte

INTRODUCTION

Metabolic syndrome (MS) is introduced in 1988 by Reaven and colleagues, and can be elucidated as a constellation of various metabolic disorders, such as obesity, glucose intolerance, elevated triacylglycerol level, low HDL-cholesterol level, and elevated blood pressure¹⁻³. MS substantially increases the risk of cardiovascular and cerebrovascular diseases, as well as type 2 diabetes mellitus⁴. People with MS are also more prone to develop organ-related abnormalities, including non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), along with various organ dysfunction, infertility, dementia, and obstructive sleep disorders^{1,3-5}. Moreover, MS is correlated with an increased incidence, morbidity, and mortality of cancers involving the liver, pancreas, cervix, and breast^{1,6,7}.

The global prevalence of MS grows at an alarming rate, now ranges from 20% to 30% of the world's adult population^{8,9}. The prevalence is expected to escalate due to increasing prevalence of obesity, excessive consumptions of calorie-dense foods and sugary drinks, as well as sedentary lifestyles^{2,10}. Visceral obesity plays an essential factor for chronic inflammation, hyperlipidemia, insulin resistance, and cardiovascular disorders¹¹. Visceral adipocytes are typically larger in size and release several pro-inflammatory mediators, including prostaglandins, C-reactive protein,

1. Islamic University of Indonesia, Yogyakarta, Indonesia.

Correspondence

Evyy Sulistyoningrum, Department of Histology and Biology, Faculty of Medicine, Islamic University of Indonesia, Yogyakarta, Indonesia,

and various cytokines, which contribute to an increased risk of metabolic disorders including type 2 diabetes mellitus, hyperlipidemia, and cardiovascular disease^{12,13}.

Eugenia uniflora L. (*Myrtaceae*) is a native Brazilian plant that grows broadly in various tropical regions and has been conventionally used for its antidiabetic, antidiarrheal, diuretic, and antihypertension properties^{14,15}. Several studies also highlighted its potential antioxidant, antimicrobial, cytoprotective, nephroprotective, and anti-neoplastic effects¹⁶⁻¹⁹. Among its plant parts, the fruits and leaves of *E. uniflora* have been extensively investigated¹⁵. Given the limited availability of the fruit and the abundance of leaves with promising pharmacological potential, this study aims to investigate the activity of *E. uniflora* leaf extract on metabolic parameters, visceral fat, and pancreatic histology in a rat model of metabolic syndrome.

MATERIALS AND METHODS

Extract preparation

About 500 g of fresh leaves of *E. uniflora* were gathered in April 2024 from a tree planted in Sleman, Yogyakarta, Indonesia (GPS coordinates -7.703718/S7°42'13.387", 110.427723/E110°25'39.801"). Plant specimen was collected in the herbarium and identified by the Faculty of Biology, Gadjah Mada University (00608/S.Tb/IV/2024). The leaves were dried at 40°C and ground to obtain 300 g of powder. All simplisia were then soaked with 5 L of 96% ethanol for 3 days and then filtered. All filtrates were then evaporated by rotary evaporation (50 °C; 178 mbar; 60 rpm), resulting in the 48.05 g crude extract (16.02% yield)¹⁷. The extraction was executed at the Pharmaceutical Biology Laboratory, Islamic University of Indonesia.

Experimental animals and intervention

Twenty-five male *Rattus norvegicus* (Wistar strain) aged 8-10 weeks and weighing 175 ± 25 g were used in this study. The number of animals was determined according to the Festing formula for experimental design²⁰. Prior to treatment, all animals were acclimatized for seven days under standard laboratory conditions. They were maintained in group cages with controlled environmental parameters, including 12 hours dark/light cycle, ambient temperature $22 \pm 3^\circ\text{C}$, approximately 40% relative humidity. The experiment was executed at the Integrated Research Laboratory, Islamic University of Indonesia. Rats had free access

to standard chow and tap water for seven days of adaptation and then randomly assigned into five groups using a random number generator: control, untreated metabolic syndrome model (MS), MS received telmisartan 8 mg/kg as standard treatment (MS+TMS), MS received ELE 50 mg/kg (MS+ELE50), and MS received ELE 100 mg/kg (MS+ELE100). Metabolic syndrome was induced by gavaging an oxidized oil and quail egg yolk combination (1:2) and 20% D-fructose as drinking water (FDW) (Merck Milipore, Indonesia) for 56 days^{21,22}. All treatment regimens and doses were determined and given simultaneously as an oral solution not exceeding 1 ml/g/day every 8 a.m (Figure 1)^{23,24}.

Anthropometric and Blood Pressure Measurements

The nasoanal length of each rat was determined by measuring the distance from the tip of the nose to the anus using a calibrated graph. Body weight was recorded with a calibrated digital scale (Quattro; Indonesia). Lee indexes were calculated according to the following formula:²⁵

$$\text{Lee index} = \frac{\sqrt[3]{\text{Body weight (g)}}}{\text{Nasoanal length (cm)}} \times 1,000$$

Blood pressures were recorded using a non-invasive blood pressure system (Panlab LE 5002, Harvard Apparatus; Canada) following a two-day adaptation period to the apparatus. Three consecutive readings were taken for each rat and the mean value was considered for analysis.

Biochemical Parameter Measurements

On day 57, all rats were anesthetized with an intraperitoneal injection of ketamine (25 mg/kg; Sandoz, Canada) following 12-h fasting period. Blood samples were collected from the retro-orbital plexus and centrifuged at $1,500 \times g$ for 15 min to prepare plasma, which was preserved at -20°C until analysis. Biochemical parameters were determined using commercial assay kits (Wako Pure Chemical Industries, Japan)²⁵.

Histological Preparation and Examination

After all animals were euthanized using the guillotine, a longitudinal incision was performed, and internal organs were visualized. Pancreas and adipose tissue surrounding the testis and epididymis were taken²⁶.

Epididymal fat was processed into 5 µm paraffin-tissue sections, deparaffinized, and stained with hematoxylin-eosin (HE). Adipocyte tissue was determined in five representative photomicrographs taken from a CX22 light microscope (Olympus, Japan) equipped with Optilab Viewer imaging system (Miconos, Indonesia). Adipocyte area (µm²) was quantified with ImageJ FIJI software, version 2.0 (National Institutes of Health,

Bethesda, MD, USA) at 10X magnification using the Adiposoft plugin version 1.16 using manual edition and exclusion of the cell located at the edge to enhance accuracy^{27–29}. Pancreatic islet parameters were measured on five representative fields at 400X magnification. The diameter was taken twice, at the maximum transverse diameter of islets and perpendicular to the previous. The transversal diameter were calculated based on the

Formula³⁰:

Transvertical diameter

$$= \frac{(\text{maximum transverse diameter} + \text{maximum perpendicular diameter})}{2}$$

The measurement was performed independently by two observers blinded to the treatment, and the Intraclass Correlation Coefficient (ICC) value was 0.96, indicating an excellent agreement (ICC value > 0.90)³¹.

Statistical analysis

Statistical analysis were performed with GraphPad software version 9.3.1. Data normality was verified using the Shapiro-Wilk test. All result were presented as mean ± standard deviation. Group differences were assessed by one-way ANOVA followed by appropriate post hoc comparisons, and p values below 0.05 were considered statistically significant.

Ethical Considerations

Ethical approval was obtained from the Health Research Ethics Committee, Faculty of Medicine, Islamic University of Indonesia (5/Ka.Kom.Et/70/KE/XII/2023).

RESULTS

E. uniflora extract and telmisartan improved the metabolic syndrome component

As shown in Figure 2, treatments exerted distinct effects on the components of MS. The MS group demonstrated a significant elevated glucose levels compared with controls. Treatment with 100 mg/kg ELE effectively lowered glucose levels, comparable to the effect observed with telmisartan. In addition, both systolic and diastolic blood pressure were significantly higher in the MS group. Notably, ELE 100 mg/kg significantly decreased systolic blood pressure similar with telmisartan's effect. However, we did not find a similar effect on diastolic blood pressure. The Lee index, as

a surrogate marker of obesity in rodents, increased in the MS group, and ELE treatment attenuated this in a dose-dependent manner. The triglyceride levels were significantly elevated in the MS group. Treatment with ELE 100 mg/kg significantly reduced triglyceride levels comparable to telmisartan. HDL-cholesterol was also reduced in the MS group. Administration of 100 mg/kg ELE led to a significant increase in HDL levels, restoring them closer to control value. Taken together, the data in Figure 2 indicate that ELE exerts beneficial effects on MS components, comparable to telmisartan.

E. uniflora leaf extract and telmisartan reduced epididymal adiposity.

Figure 3 illustrates the effect of treatments on epididymal fat; panels A–E present histological sections, while panel F quantitatively summarizes the mean fat cell area for each group. The control group shows tightly packed adipocytes of relatively small and uniform size. In contrast, the MS group reveals enlarged adipocytes with significant hypertrophy. Treatment with telmisartan resulted in a marked reduction in adipocyte size compared with the MS group. A comparable, though moderate, decrease in adipocyte size was also observed in the MS + ELE50 group. Notably, panel E displays adipocyte morphology resembling that of the control group, characterized by diminished hypertrophy and improved cellular uniformity. Quantitative analysis of fat area (panel F) revealed a significant enlargement of adipocyte in the MS group relative to the control. Both telmisartan and ELE at 50 mg/kg and 100 mg/kg significantly decreased fat area compared with the MS group, with the higher ELE dose (100 mg/kg) producing an effect comparable to telmisartan.

E. uniflora leaf extract and telmisartan attenuated pancreatic damage

Figure 4 presents histopathological evidence of the pancreas. Image A depicts a pancreas from the control group, showing intact pancreatic acini and well-preserved pancreatic islets. In contrast, the MS group reveals pronounced pathological alterations, including extensive acinar and insular vacuolization, adipocyte infiltration, chronic inflammation, and fibrosis. The MS + ELE50 group demonstrates notable abnormalities, although the severity appears attenuated. Panels D and E are higher magnifications of the boxed regions in B, highlighting pancreatic injury in the MS group, including adipose infiltration, chronic inflammation, fibrotic areas, and multiple vacuolated islet cells and adjacent adipocytes. Panel F further emphasizes insular vacuolization in the MS + ELE50 group, demonstrating clear disruption of islet integrity and insular vacuolization. The lower panel of the figure provides a qualitative summary of the pathological changes across groups. The MS group shows acinar and insular vacuolization along with inflammation and fibrosis. Treatment with telmisartan ameliorated these changes, as evidenced by the absence of pathological features. The MS + ELE50 group displayed acinar and insular vacuolization, but no signs of inflammation or fibrosis, indicating partial protection. Interestingly, the MS + ELE100 group showed only mild insular vacuolization, suggesting a dose-dependent protective effect of ELE against MS-induced pancreatic injury.

E. uniflora leaf extract and telmisartan did not affect pancreatic islet diameter and area

The upper panels (A–F) in Figure 5 illustrates pancreatic morphological differences, while the lower panel quantifies pancreatic islet diameter and area. Panel A displays normal and compact pancreatic islet structure surrounded by intact acinar cells (control group). In contrast, panels B and C reveal signs of islet and acinar vacuolization observed in the MS group. Panel D and E show reduced insular vacuolization, suggesting partial recovery or attenuation of the pancreatic damage with either telmisartan or low-dose ELE treatment. Notably, panel F (MS + ELE100) shows a largely preserved pancreatic islet with normal morphology. However, the quantitative analysis in the lower panel indicates no differences in pancreatic islet diameter or area among groups. These findings suggest that while metabolic syndrome induces cellular-level changes such as

vacuolization, it does not significantly affect islet size.

Discussion

This current research highlights the potential of *E. uniflora* leaf extract in mitigating metabolic abnormalities, visceral adiposopathies, as well as pancreatic changes in a rat model of metabolic syndrome. The findings indicate that MS induces significant disturbances in metabolic parameters as well as in the morphology of pancreatic and adipose tissues, all of which were ameliorated by ELE, particularly at the dose of 100 mg/kg.

Our study reported that the HFD and 20% FDW significantly induced MS traits such as hyperglycemia, hypertriglyceridemia, hypo-HDL-cholesterolemia, hypertension, and obesity. Previous research have demonstrated alterations in clinical parameters--including elevated fasting glucose, triglyceride levels, and body weight relevant--in animals fed a HFD combined with fructose-drinking water, reflecting metabolic syndrome conditions. This model has also been shown to increase the adiposity index, induce insulin resistance, elevate pro-inflammatory cytokines, and cause histomorphometric alteration in the liver, pancreas, and adipose tissue^{32,33}. Compared with other methods, this combination of diets has several advantages, even though HFD and fructose alone may cause changes in metabolic and target-organ abnormalities^{34,35}. The model closely reflects current eating habits trend in the society, where HFD contribute to obesity, and excessive fructose intake leads to elevated triglyceride levels. Such a diet also decreases HDL-C and elevates plasma cholesterol, representing a typical pattern of dyslipidemia^{34–37}.

Obesity traits in metabolic syndrome were also reported to promote adipocytes' hypertrophy and pancreatic steatosis^{32,38}. HFD is usually accompanied by insulin resistance, resulting in cellular condensation and atrophy, inflammation, and peri-insular fibrosis³⁴. Insulin resistance plays a crucial role in promoting lipid accumulation within both adipose and the pancreas, consequently leading to chronic inflammation^{39,40}. The accumulation of visceral fat will undergo lipolysis and increase the supply of free fatty acids to the target organs⁴¹. This condition can lead to cytoplasm vacuolization, irregularity in β -cells' nuclear shape, and nucleolar segmentation, while in α -cells, MS can lead to increased glucagon expression, chromatin condensation, and diminished cell boundaries³⁹. On the

other hand, increased blood glucose levels and free fatty acids can trigger β -cell hyperplasia and hypertrophy via expression of cyclin-D2 activated by the protein kinase C (PKC)-phosphatidylinositol-3 kinase (PI3K) pathway and cause the size of the islets of Langerhans to enlarge^{42,43}.

Both telmisartan and ELE reduced these clinical and microstructural abnormalities, with the higher dose of ELE showing efficacy comparable to telmisartan, particularly in reducing blood glucose, triglycerides, and systolic blood pressure. This finding is consistent with previous reports demonstrating the protective effect of *E. uniflora* leaf extract, obtained through various extraction methods, in both *in vitro* and *in vivo* models of MS. *E. uniflora* leaf extract has been reported to orchestrate enzymatic processes related to metabolism, exhibit antioxidant activity, and reduce glycation in *in vitro* studies. In *in vivo* experiments, the extract demonstrated protective effects characterized by enhanced insulin secretion and insulinotropic activity; increased serum antioxidant capacity; reduced serum glucose levels, elevated HDL-cholesterol; and decreased lipid parameters. Phytochemical analyses have revealed that the extract contains various bioactive constituents, such as alkaloids, flavonoids, phenolic components—primarily ellagic acid, gallic acid, rutin, quercetin, and valoneic acid), myricetin, terpenes, tannins, and phenolic acids⁴⁴. Other studies have reported the clinical benefits and antioxidant effects of chronic administration of ELE in non-obese diabetic mice, as evidenced by the maintenance of normal serum insulin levels, reduced serum lipid peroxidation, and protection of target organs such as the liver and pancreas. These protective effects were further supported by a decreased inflammatory index in the pancreatic islets of Langerhans and an increase in hepatic glutathione levels⁴⁵.

Earlier research demonstrated that *E. uniflora* extract exerts protective actions in rats subjected to a high-palatable diet-induced model of metabolic syndrome. The extract reduced serum IL-6 levels and enzymes responsible for inflammatory and thromboregulatory modulation, such as adenosine deaminase, nucleoside triphosphate diphosphohydrolases, acetylcholinesterase, and butyrylcholinesterase⁴⁶. Similar results were also reported on metabolic alterations and oxidative markers of the dexamethasone-induced insulin-resistance rat model⁴⁷.

Phytochemical analysis revealed that *E. uniflora* leaf

extracts were rich in flavonoids, phenols, saponins, and tannins, and the extract also exhibited very strong antioxidant activity in ABTS *in vitro* methods⁴⁸. Phenolic compounds contained in *E. uniflora* extract, such as quercetin, provide antioxidant effects by scavenging free radicals produced from lipid peroxidation. The benefit of *E. uniflora* extract administration was not limited to the metabolic alteration but also affected the neurostructure of the hippocampus and striatum, improving neurochemical parameters and behavioral parameters of the rats⁴⁹. Analysis by high-performance liquid chromatography with photodiode array detection revealed that the crude extract and fractionated extract of *E. uniflora* leaves contain several bioactive constituents, including gallic acid, ellagic acid, and myricitrin. These extracts demonstrated notable antibacterial, anti-inflammatory, and antioxidant activities⁵⁰.

This current study has several limitations. First, the direct molecular mechanisms have not been investigated yet. Second, the study did not evaluate insulin levels or glucose tolerance, which would provide insight into β -cell function and insulin sensitivity, and finally, long-term safety and pharmacokinetic profiles of *E. uniflora* extract were not assessed yet.

CONCLUSION

In conclusion, *Eugenia uniflora* leaf extract effectively ameliorated multiple components of MS in rats, including metabolic disturbances, adipocyte hypertrophy, and pancreatic damage. Its therapeutic effect, particularly at 100 mg/kg, was comparable to telmisartan in many respects, supporting the potential of *E. uniflora* leaf extract as a natural adjunctive therapy for MS, although further studies are required to clarify its molecular mechanisms and long-term safety in clinical settings.

Funding

This work was financially supported by an internal research grant from Faculty of Medicine, Islamic University of Indonesia.

Acknowledgements

The authors would like to acknowledge; Ernadita Budiasri and Arini Rizky Wijayanti for assistance.

Conflicts of interest

None to declare.

Ethical Clearance

Ethical clearance was obtained from the Health

Research Ethics Committee, Faculty of Medicine, Islamic University of Indonesia (5/Ka.Kom.Et/70/KE/XII/2023).

Declaration of Use of AI in Scientific Writing

During the manuscript preparation, the authors used QuillBot to correct any grammatical errors and free version of Biorender to create the image (<https://www.biorender.com/>). After using this tool/service, the authors reviewed and edited the content as required.

Authors' Contributions

Data gathering and idea owner of this study: Evy Sulistyoningrum

Study design: Evy Sulistyoningrum

Data gathering: Dede Syifa Izzatul Aulia, Evy Sulistyoningrum

Writing and submitting manuscript: Dede Syifa Izzatul Aulia, Evy Sulistyoningrum

Editing and approval of final draft: Dede Syifa Izzatul Aulia, Evy Sulistyoningrum




Figure 1. Schematic diagram of the research intervention




Figure 2. Effect of *E.uniflora* leaf extract on the metabolic syndrome components. MS: metabolic syndrome, MS + TMS: metabolic syndrome + telmisartan 8 mg/kg, MS + ELE50: metabolic syndrome + *E.uniflora* leaf extract 50 mg/kg; MS + ELE100: metabolic syndrome + *E.uniflora* leaf extract 100 mg/kg. * $p < 0.05$, ** $p < 0.01$ compared with MS (ANOVA and post-hoc test)





Figure 3. Effect of *E.uniflora* leaf extract on the fat area. A. Control, B. MS: metabolic syndrome. C. MS + TMS: metabolic syndrome + telmisartan 8 mg/kg, D. MS + ELE50: metabolic syndrome + *E.uniflora* leaf extract 50 mg/kg; E. MS + ELE100: metabolic syndrome + *E.uniflora* leaf extract 100 mg/kg. * $p < 0.05$, ** $p < 0.01$ compared with MS (ANOVA and post-hoc test). Bar: 100 μm .



Group	Acinar Vacuolization	Insular Vacuolization	Inflammation and fibrosis
Control	0	0	0
MS	++	++	++
MS + TMS	0	+	0
MS + ELE50	+	++	0
MS + ELE100	0	+	0

Figure 4. Histopathological changes on the pancreas. Upper panel showed normal pancreas from control (A) and abnormal pancreas from MS (B) and MS+ELE50 (C), HE staining, bar: 100 μ m; 100X. Continuous line box area was enlarged in D showing large adipocytes (yellow arrow) and lymphocytes infiltration (blue arrow) as well as fibrotic area (green arrow). Dashed line box area was enlarged in E showing vacuolization and adipocytes (yellow arrows). Insular vacuolization also observed at MS + ELE50 (C and F), 400X. Lower panel: recapitulation of qualitative pathological changes groups. MS: metabolic syndrome; MS + ELE50: metabolic syndrome + *E.uniflora* leaf extract 50 mg/kg. PA: pancreatic acini, PI: pancreatic islet.





Figure 5. High magnification of pancreatic islets among groups. Upper panel showed normal islet in Control group (A), acinar vacuolization (black arrow) and insular vacuolization (yellow arrow) were observed in MS group (B and C). Insular vacuolization also observed at MS + TMS and MS + ELE50 (D and E) but markedly reduced in MS + ELE100 (F). Lower panel: There were no difference in diameter (A) and area (B) of the Langerhans islets among groups. MS: metabolic syndrome; MS + TMS: metabolic syndrome + telmisartan 8 mg/kg; MS + ELE50: metabolic syndrome + *E.uniflora* leaf extract 50 mg/kg; MS + ELE100: metabolic syndrome + *E.uniflora* leaf extract 100 mg/kg HE staining, bar: 100 μm , 400X.

REFERENCES

1. Dobrowolski P, Prejbisz A, Kurylowicz A, Baska A, Burchardt P, Chlebus K, et al. Metabolic syndrome a new definition and management guidelines. *Archives of Medical Science*. 2022;**18**(5):1133-56. <https://doi.org/10.5114/aoms/152921>
2. Fahed G, Aoun L, Zerdan MB, Allam S, Zerdan MB, Bouferaa Y, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Vol. 23, *International Journal of Molecular Sciences*. MDPI; 2022. <https://doi.org/10.3390/ijms23020786>
3. Al-Mahmood A, Afrin S, Hoque N. Metabolic Syndrome and Insulin Resistance: Global Crisis. *Bangladesh J Med Biochem*. 2011;**4**(1):27-31. <https://doi.org/10.3329/bjmb.v4i1.13779>
4. O'Neill S, O'Driscoll L. Metabolic syndrome: A closer look at the growing epidemic and its associated pathologies. *Obesity Reviews*. 2015 Jan 1;**16**(1):1-12. <https://doi.org/10.1111/obr.12229>
5. Machado-Fragua MD, Fayosse A, Yerramalla MS, van Sloten TT, Tabak AG, Kivimaki M, et al. Association of Metabolic Syndrome With Incident Dementia: Role of Number and Age at Measurement of Components in a 28-Year Follow-up of the Whitehall II Cohort Study. *Diabetes Care*. 2022 Sep 1;**45**(9):2127-35. <https://doi.org/10.2337/dc22-0206>
6. Uzunlulu M, Telci O, AYTEKIN C. Association between Metabolic Syndrome and Cancer. *Ann Nutr Metab*. 2016;**68**:173-9. <https://doi.org/10.1159/000443743>
7. Ashique S, Upadhyay A, Kumar N, Chauhan S, Mishra N. Metabolic syndromes responsible for cervical cancer and advancement of nanocarriers for efficient targeted drug delivery- A review. Vol. 4, *Advances in Cancer Biology - Metastasis*. Elsevier Inc.; 2022. <https://doi.org/10.1016/j.adcanc.2022.100041>
8. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. *Curr Hypertens Rep*. 2018;**20**(12):1-8. <https://doi.org/10.1007/s11906-018-0812-z>
9. Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis. Vol. 13, *Diabetology and Metabolic Syndrome*. BioMed Central Ltd; 2021. <https://doi.org/10.1186/s13098-021-00641-8>
10. Al-Mahmood A, Afrin S, Hoque N. Metabolic Syndrome and Insulin resistance: Etiopathogenesis and influencing factors. *Bangladesh J Med Biochem*. 2011;**4**(2):26-31. <https://doi.org/10.3329/bjmb.v4i2.13773>
11. Paley CA, Johnson MI. Abdominal obesity and metabolic syndrome: Exercise as medicine? Vol. 10, *BMC Sports Science, Medicine and Rehabilitation*. BioMed Central Ltd.; 2018. <https://doi.org/10.1186/s13102-018-0097-1>
12. Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Vol. 7, *Frontiers in Cardiovascular Medicine*. Frontiers Media S.A.; 2020. <https://doi.org/10.3389/fcvm.2020.00022>
13. Lempes IG, Tsilingiris D, Liu J, Dalamaga M. Of mice and men: Considerations on adipose tissue physiology in animal models of obesity and human studies. *Metabol Open*. 2022 Sep;**15**:100208. <https://doi.org/10.1016/j.metop.2022.100208>
14. de Brito WA, Ferreira MRA, de Sousa Dantas D, Soares LAL. Biological activities of *Eugenia uniflora* L. (pitangueira) extracts in oxidative stress-induced pathologies: A systematic review and meta-analysis of animal studies. Vol. 20, *PharmaNutrition*. Elsevier B.V.; 2022. <https://doi.org/10.1016/j.phanu.2022.100290>
15. Fidelis EM, Savall ASP, de Oliveira Pereira F, Quines CB, Ávila DS, Pinton S. Pitanga (*Eugenia uniflora* L.) as a source of bioactive compounds for health benefits: A review. Vol. 15, *Arabian Journal of Chemistry*. Elsevier B.V.; 2022. <https://doi.org/10.1016/j.arabjc.2022.103691>
16. Cunha FAB, Pinho AI, Santos JFS, Sobral-Souza CE, Albuquerque RS, Matias EFF, et al. Cytoprotective effect of *Eugenia uniflora* L. against the waste contaminant mercury chloride. *Arabian Journal of Chemistry*. 2019 Dec 1;**12**(8):4197-203. <https://doi.org/10.1016/j.arabjc.2016.04.018>
17. Meira EF, Oliveira ND, Mariani NP, Porto ML, Severi JA, Siman FDM, et al. *Eugenia uniflora* (pitanga) leaf extract prevents the progression of experimental acute kidney injury. *J Funct Foods*. 2020 Mar 1;**66**: <https://doi.org/10.1016/j.jff.2020.103818>
18. Victoria FN, Lenardão EJ, Savegnago L, Perin G, Jacob RG, Alves D, et al. Essential oil of the leaves of *Eugenia uniflora* L.: Antioxidant and antimicrobial properties. *Food and Chemical Toxicology*. 2012 Aug;**50**(8):2668-74. <https://doi.org/10.1016/j.fct.2012.05.002>
19. Núñez JG, Pinheiro JDS, Silveira GF, Beckenkamp A, Buffon A, Bruno AN. Antineoplastic potential of the aqueous crude extract of *eugenia uniflora* L. in human cervical cancer. *Brazilian Journal of Pharmaceutical Sciences*. 2018;**54**(2). <https://doi.org/10.1590/s2175-97902018000217267>
20. Arifin WN, Zahiruddin WM. Sample size calculation in animal studies using resource equation approach. *Malaysian Journal of Medical Sciences*. 2017 Sep 1;**24**(5):101-5. <https://doi.org/10.21315/mjms2017.24.5.11>
21. Aji FB, Setyawan NA, Hakim FA, Pesik RN. Effect of Moringa Leaves Ethanol Extract (*Moringa oleifera*, Lam.) on Testicles Histopathological Structure in Metabolic Syndrome Rat Model. *Smart Medical Journal*. 2023 May 16;**6**(1):42. <https://doi.org/10.13057/smj.v6i1.69243>
22. Mamikutty N, Thent ZC, Sapri SR, Sahrudin NN, Mohd Yusof MR, Haji Suhaimi F. The establishment of metabolic syndrome model by induction of fructose drinking water in male Wistar rats. *Biomed Res Int*. 2014;2014. <https://doi.org/10.1155/2014/263897>

23. Nilamsari KA, Fatimah N, Prabowo GI. Antiangiogenesis Activity of Dewandaru (*Eugenia uniflora* L.) Leaf Extract in Wistar Rats Retina Induced Streptozotocin. *Jurnal Medik Veteriner*. 2020 Apr 1;**3**(1):9-16. <https://doi.org/10.20473/jmv.vol3.iss1.2020.9-16>
24. Cheng KC, Li Y, Chang WT, Kuo FY, Chen ZC, Cheng JT. Telmisartan is effective to ameliorate metabolic syndrome in rat model - A preclinical report. *Diabetes, Metabolic Syndrome and Obesity*. 2018;**11**:901-11. <https://doi.org/10.2147/DMSO.S187092>
25. Hioki C, Yoshida T, Kogure A, Yoshimoto K, Shimatsu A. Growth Hormone Administration Controls Body Composition Associated with Changes of Thermogenesis in Obese KK-Ay Mice. *Open Endocrinol J*. 2010 Apr 7;**4**(1):3-8. <https://doi.org/10.2174/1874216501004010003>
26. Luong Q, Huang J, Lee KY. Deciphering white adipose tissue heterogeneity. *Biology (Basel)*. 2019 Jun 1;**8**(2). <https://doi.org/10.3390/biology8020023>
27. Galarraga M, Campión J, Muñoz-Barrutia A, Boqué N, Moreno H, Martínez JA, et al. Adiposoft: Automated software for the analysis of white adipose tissue cellularity in histological sections. *J Lipid Res*. 2012 Dec;**53**(12):2791-6. <https://doi.org/10.1194/jlr.D023788>
28. Pilling D, Karhadkar TR, Gomer RH. High-Fat Diet-Induced Adipose Tissue and Liver Inflammation and Steatosis in Mice Are Reduced by Inhibiting Sialidases. *American Journal of Pathology*. 2021 Jan 1;**191**(1):131-43. <https://doi.org/10.1016/j.ajpath.2020.09.011>
29. Grzesiak M, Burzawa G, Kurowska P, Blaszczyk K, Szlaga A, Blasiak A, et al. Altered vitamin D3 metabolism in the ovary and periovarian adipose tissue of rats with letrozole-induced PCOS. *Histochem Cell Biol*. 2021 Jan 1;**155**(1):101-16. <https://doi.org/10.1007/s00418-020-01928-z>
30. Baneswar B, Gunamani R, Usha S, Talukdar K, Dutta B, Tapan S. A Study of Human Cadaveric Pancreas: Variations in the Diameters of Islets of Langerhans in Different Age Group. *Paripex-Indian Journal of Research [Internet]*. 2021;**10**(3):18-21. Available from: www.worldwidejournals.com <https://doi.org/10.36106/2600886>
31. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. *J Chiropr Med*. 2016 Jun 1;**15**(2):155-63. <https://doi.org/10.1016/j.jcm.2016.02.012>
32. Melo BP, Zacarias AC, Oliveira JCC, de Souza LMC, Sabino J, Ferreira AVM, et al. Thirty days of combined consumption of a high-fat diet and fructose-rich beverages promotes insulin resistance and modulates inflammatory response and histomorphometry parameters of liver, pancreas, and adipose tissue in Wistar rats. *Nutrition*. 2021 Nov 1;91-92. <https://doi.org/10.1016/j.nut.2021.111403>
33. Hidayati L, Widodo ADW, Hidayat B. Animal Models with Metabolic Syndrome Markers Induced by High Fat Diet and Fructose. *Medical Laboratory Technology Journal*. 2020 Jan 3;**1**(1). <https://doi.org/10.31964/mltj.v1i1.266>
34. Albrahim T, Alonazi MA. Lycopene corrects metabolic syndrome and liver injury induced by high fat diet in obese rats through antioxidant, anti-inflammatory, antifibrotic pathways. *Biomedicine and Pharmacotherapy*. 2021 Sep 1;141. <https://doi.org/10.1016/j.biopha.2021.111831>
35. Ferreira-Santos P, Aparicio R, Carrón R, Montero MJ, Sevilla M. Lycopene-supplemented diet ameliorates metabolic syndrome induced by fructose in rats. *J Funct Foods*. 2020 Oct 1;**73**: <https://doi.org/10.1016/j.jff.2020.104098>
36. Gunawan S, Munika E, Wulandari ET, Ferdinal F, Purwaningsih EH, Wuyung PE, et al. 6-gingerol ameliorates weight gain and insulin resistance in metabolic syndrome rats by regulating adipocytokines. *Saudi Pharmaceutical Journal*. 2023 Mar 1;**31**(3):351-8. <https://doi.org/10.1016/j.jsps.2023.01.003>
37. Gunawan S, Aulia A, Soetikno V. Development of rat metabolic syndrome models: A review. Vol. 14, *Veterinary World*. *Veterinary World*; 2021. p. 1774-83. <https://doi.org/10.14202/vetworld.2021.1774-1783>
38. Petrovic S, Mouskeftara T, Paunovic M, Deda O, Vucic V, Milosevic M, et al. Unveiling Lipidomic Alterations in Metabolic Syndrome: A Study of Plasma, Liver, and Adipose Tissues in a Dietary-Induced Rat Model. *Nutrients*. 2024 Oct 1;**16**(20). <https://doi.org/10.3390/nu16203466>
39. Ergashev S, Usmanov R, Niyozov N. Morpho-Functional Changes In The Endocrine Pancreas Of White Rats Under Metabolic Syndrome Conditions. *Central Asian Journal of Medicine [Internet]*. 2025 [cited 2025 Jun 16];**4**(4):75-80. Available from: <https://journals.tma.uz/index.php/cajm/article/view/1358>
40. Pal SC, Méndez-Sánchez N. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. Vol. 29, *World Journal of Gastroenterology*. *Baishideng Publishing Group Inc*; 2023. p. 3999-4008. <https://doi.org/10.3748/wjg.v29.i25.3999>
41. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: Pathophysiology, management, and modulation by natural compounds. Vol. 11, *Therapeutic Advances in Cardiovascular Disease*. *SAGE Publications Ltd*; 2017. p. 215-25. <https://doi.org/10.1177/1753944717711379>
42. Hatanaka M, Anderson-Baucum E, Lakhter A, Kono T, Maier B, Tersey SA, et al. Chronic high fat feeding restricts islet mRNA translation initiation independently of ER stress via DNA damage and p53 activation. *Sci Rep*. 2017 Dec 1;**7**(1). <https://doi.org/10.1038/s41598-017-03869-5>
43. Lakshmipathi J, Alvarez-Perez JC, Rosselot C, Casinelli GP, Stamateris RE, Rausell-Palamos F, et al. PKC ζ is essential for pancreatic β -cell replication during insulin resistance by regulating mTOR and cyclin-D2. *Diabetes*. 2016 May 1;**65**(5):1283-96. <https://doi.org/10.2337/db15-1398>

44. Peixoto Araujo NM, Arruda HS, de Paulo Farias D, Molina G, Pereira GA, Pastore GM. Plants from the genus *Eugenia* as promising therapeutic agents for the management of diabetes mellitus: A review. Vol. 142, Food Research International. Elsevier Ltd; 2021. <https://doi.org/10.1016/j.foodres.2021.110182>
45. Schumacher NSG, Colomeu TC, de Figueiredo D, Carvalho V de C, Cazarin CBB, Prado MA, et al. Identification and antioxidant activity of the extracts of *Eugenia uniflora* leaves. Characterization of the anti-inflammatory properties of aqueous extract on diabetes expression in an experimental model of spontaneous type 1 diabetes (NOD mice). *Antioxidants*. 2015 Dec 1;**4**(4):662-80. <https://doi.org/10.3390/antiox4040662>
46. Oliveira PS, Soares MSP, Bona NP, da Silva PG, Mendonça LT, Vieira A, et al. Brazilian native fruit extracts act as preventive agents modulating the purinergic and cholinergic signalling in blood cells and serum in a rat model of metabolic syndrome. *Arch Physiol Biochem*. 2022;**128**(4):993-1000. <https://doi.org/10.1080/13813455.2020.1743723>
47. de Souza Cardoso J, Oliveira PS, Bona NP, Vasconcellos FA, Baldissarelli J, Vizzotto M, et al. Antioxidant, antihyperglycemic, and antidyslipidemic effects of Brazilian-native fruit extracts in an animal model of insulin resistance. *Redox Report*. 2018 Jan 1;**23**(1):41-6. <https://doi.org/10.1080/13510002.2017.1375709>
48. Anwar K, Lokana FM, Budiarti A. Antioxidant Activity of Dewandaru Leaf (*Eugenia Uniflora* L.) Ethanol Extract and Determination of Total Flavonoid and Phenolic Content. *JURNAL ILMIAH SAINS*. 2022 Oct 31;**22**(2):161-71. <https://doi.org/10.35799/jis.v22i2.43913>
49. Oliveira PS, Chaves VC, Bona NP, Soares MSP, Cardoso J de S, Vasconcellos FA, et al. *Eugenia uniflora* fruit (red type) standardized extract: a potential pharmacological tool to diet-induced metabolic syndrome damage management. *Biomedicine and Pharmacotherapy*. 2017 Aug 1;**92**:935-41. <https://doi.org/10.1016/j.biopha.2017.05.131>
50. Falcão TR, de Araújo AA, Soares LAL, de Moraes Ramos RT, Bezerra ICF, Ferreira MRA, et al. Crude extract and fractions from *Eugenia uniflora* Linn leaves showed anti-inflammatory, antioxidant, and antibacterial activities. *BMC Complement Altern Med*. 2018 Mar 9;**18**(1). <https://doi.org/10.1186/s12906-018-2144-6>